Share this page

Efficacy, Tolerability and Safety of IVIg (octagam® 10%) in Adult Patients with Active Dermatomyositis

ProDERM Trial

This component is used for live events. A user needs to register via the form that is provided here. Registering via the form results in a non validated ScienceHub member that only has access to the eventpage.

cxm-live-event

Auth CXM Event Acess - without login

Efficacy, Tolerability and Safety of IVIg (octagam® 10%) in Adult Patients with Active Dermatomyositis - successfully meeting the primary endpoint

[YOUR MESSAGE]%0D%0A%0D%0A%0D%0ALocation: ${location}%0D%0A%0D%0AReport:%0D%0A${report}

ProDERM Trial

Register here

Share this page